Status:

COMPLETED

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

Lead Sponsor:

Zentrum für Integrative Psychiatrie

Collaborating Sponsors:

Stanley Medical Research Institute

Conditions:

Schizophrenia

Major Depression

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As...

Eligibility Criteria

Inclusion

  • Schizophrenia or Major Depression
  • Both genders
  • Adult
  • Patients are able to give informed consent

Exclusion

  • Additional diagnosis of substance abuse/dependency
  • Continuous treatment with medication not compatible with study medication
  • Medical status not compatible with study medication
  • Any condition that increases study risk considerably
  • Pregnancy, nursing

Key Trial Info

Start Date :

January 1 2002

Trial Type :

INTERVENTIONAL

End Date :

September 1 2005

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00300404

Start Date

January 1 2002

End Date

September 1 2005

Last Update

May 22 2006

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression | DecenTrialz